Separately, Zacks Investment Research raised Vaccinex from a sell rating to a hold rating in a research note on Friday, July 19th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of Buy and an average price target of $17.58.
Vaccinex stock traded up $0.39 during midday trading on Thursday, reaching $4.79. 5,366 shares of the stock traded hands, compared to its average volume of 10,079. The business’s fifty day moving average price is $4.85. Vaccinex has a 12 month low of $3.32 and a 12 month high of $12.00. The company has a market cap of $52.27 million and a PE ratio of -0.92.
In related news, insider Maurice Zauderer acquired 183,824 shares of the firm’s stock in a transaction on Tuesday, July 30th. The shares were acquired at an average cost of $4.08 per share, for a total transaction of $750,001.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Albert Friedberg acquired 1,838,235 shares of the firm’s stock in a transaction on Tuesday, July 30th. The shares were bought at an average price of $4.08 per share, for a total transaction of $7,499,998.80. The disclosure for this purchase can be found here. Over the last three months, insiders have purchased 2,023,111 shares of company stock valued at $8,254,198. 69.90% of the stock is owned by corporate insiders.
A hedge fund recently bought a new stake in Vaccinex stock. Creative Planning acquired a new stake in shares of Vaccinex Inc (NASDAQ:VCNX) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,000 shares of the company’s stock, valued at approximately $55,000. Creative Planning owned 0.09% of Vaccinex at the end of the most recent reporting period. 1.57% of the stock is currently owned by institutional investors and hedge funds.
Vaccinex, Inc, a clinical-stage biotechnology company, discovers and develops bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab that is in clinical development stage for the treatment of non-small cell lung cancer (NSCLC), osteosarcoma, melanoma, and Huntington's disease.
Read More: What Factors Can Affect Return on Equity?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Vaccinex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaccinex and related companies with MarketBeat.com's FREE daily email newsletter.